Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
OPERATING ACTIVITIES    
Net income (loss) $ 2,332 $ (395)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Provision for doubtful accounts 39 (194)
Depreciation 6,166 5,438
Loss on disposal of and reserve adjustments for medical equipment 380 316
Gain on sale of medical equipment (1,723) (1,036)
Amortization of intangible assets 495 495
Amortization of deferred debt issuance costs 39 39
Stock-based compensation 1,769 2,055
Deferred income taxes 1,363 405
Changes in assets - (increase)/decrease:    
Accounts receivable (2,089) (1,203)
Inventories 863 (437)
Other current assets 24 (446)
Other assets 1,106 914
Changes in liabilities - (decrease)/increase:    
Accounts payable and other liabilities (1,975) (3,265)
NET CASH PROVIDED BY OPERATING ACTIVITIES 8,789 2,686
INVESTING ACTIVITIES    
Acquisition of business (1,412) 0
Purchase of medical equipment (4,314) (8,796)
Purchase of property and equipment (348) (519)
Proceeds from sale of medical equipment, property and equipment 1,728 2,201
NET CASH USED IN INVESTING ACTIVITIES (4,346) (7,114)
FINANCING ACTIVITIES    
Principal payments on long-term debt (30,261) (26,744)
Cash proceeds from long-term debt 32,717 31,769
Debt issuance costs (12) 0
Common stock repurchased as part of share repurchase program (6,395) (283)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (458) (624)
Cash proceeds from exercise of options and ESPP 159 225
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES (4,250) 4,343
Net change in cash and cash equivalents 193 (85)
Cash and cash equivalents, beginning of period 527 231
Cash and cash equivalents, end of period $ 720 $ 146